scholarly journals A Crohn’s Disease Patient with Extraintestinal Manifestations: A Case Report

Author(s):  
Yhan Batista ◽  
Herry Purbayu

Crohn’s disease (CD) is a chronic debilitating inflammatory disease which mostly affect gastrointestinal tract, but due to its unique features, CD enables to affect extraintestinal organs. Pathophysiology of extraintestinal manifestations is still debatable as many experts propose immune-related hypotheses. It is still unpredictable which manifestation precedes another as studies ongoing. Diagnosing CD is difficult since no gold standards available, therefore clinicians must combine history taking, diagnostic modalities, and a good clinical judgement to diagnose CD. Treatment for CD is not only to treat disease activity, but also to prevent complications to preserve patients’ quality of life.   

Doctor Ru ◽  
2020 ◽  
Vol 19 (10) ◽  
pp. 27-32
Author(s):  
А.R. Tahirova ◽  
◽  
I.V. Sichinava ◽  
O.F. Savvateeva ◽  
E.V. Borisova ◽  
...  

Study Objective: To analyse the activity dynamics of Crohn’s disease (CD) and the quality of life (QoL) of children aged 8–17 years. Study Design: Open prospective non-randomized comparative study. Materials and Methods. The quality of life was assessed in 37 healthy children and 28 children with Crohn's disease (17 boys and 11 girls). Disease activity (Paediatric Crohn’s Disease Activity Index, PCDAI) was determined using PedsQL 4.0 Generic Core Scales questionnaire which comprises assessment of health and activity, child’s attitude, problems with interpersonal relations, and progress at school. Observation spanned over 18 months; tests parameters were assessed at the beginning (first visit), after 6, 12 and 18 months. QoL was assessed by both children and their parents, the indicators were assessed over time and compared with the levels of activity, the duration of the disease, and the presence of extraintestinal manifestations of the disease. Study Results. Children with CD aged 8–17 years demonstrated a decrease in the majority of PedsQL 4.0 parameters. The shifts are observed both when QoL is assessed by children and their parents. The therapy in these patients is accompanied by positive QoL dynamics; these changes occur in parallel with a decrease in the values of the CD activity index, suggesting the possibility of using the QoL parameters to predict the course of the disease and the effectiveness of the treatment in this population. PCDAI values in subjects demonstrated moderate statistically significant negative correlations with “Physical activity” (r = –0.412), “Attitude” (r = –0.364), “Psychosocial functioning” (r = –0.306) and “School life” (r = –0.344) and the overall PedsQL 4.0 values (r = –0.406). The duration of the disease has statistically significant negative correlation with “Physical activity” (r = –0.386), “Attitude” (r = –0.423), “Psychosocial functioning” (r = –0.345), and the integral PedsQL 4.0 value (r = –0.397); the presence of extraintestinal manifestations demonstrated moderate negative correlation with “Physical activity” (r = –0.342), “School life” (r = –0.431) and overall value (r = –0.372). Conclusion. Monitoring of the health-related quality of life should become a mandatory component of the examination and management of children with inflammatory bowel diseases, since this category of patients is characterized by a significant decrease relative to the corresponding indicators in healthy peers. Keywords: inflammatory bowel disorder, Crohn’s disease, quality of life, disease activity, extraintestinal manifestations.


2016 ◽  
Vol 150 (4) ◽  
pp. S1001-S1002
Author(s):  
Doron Schwartz ◽  
Elena Chernin ◽  
Dan Greenberg ◽  
Orly Sarid ◽  
Vered Slonim-Nevo ◽  
...  

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S436-S437
Author(s):  
A Spinelli ◽  
H Yanai ◽  
S Lönnfors ◽  
P Girardi ◽  
S Milicevic ◽  
...  

Abstract Background Perianal fistulas (PAF) in Crohn’s disease (CD) may impair social performance, sexual function, life activities and overall patients’ quality of life (QoL). Patient experience is important in the treatment decision making and in providing adequate support. Despite the clinical relevance, few studies have addressed the patient perspective on the impact of PAF and complex PAF (CPAF) in CD on QoL. Methods A questionnaire assessing the impact of PAF on QoL was developed by patient representatives and medical experts addressing diagnosis, symptoms and QoL including close relationships, social life, sexual activity and working life. CD patients with and without PAF were invited to participate. The self-selective anonymous survey was available in 11 languages and accessible on the European Federation of Crohn’s & Ulcerative Colitis Associations’ (EFCCA) website and national inflammatory bowel disease patient association websites from 15 July to 31 December 2019. Results Of 820 respondents with CD (67.2% women; mean age 40.8 years), 532 (64.9%) reported PAF in CD of which 272 (51.1%) reported CPAF. PAF/CPAF patients had experienced and were currently experiencing more anal pain and perianal leaking than CD patients (Figure). On a 10-point scale, PAF/CPAF patients reported a greater impact on overall QoL (6.91 vs 6.18, p<0.001), relationships with family and friends (5.54 vs 4.78, p<0.001), relationship with partner (5.24 vs 4.11, p<0.001), social life (5.65 vs 4.97, p=0.001) and working life (5.54 vs 5.12, p=0.02) than CD patients. PAF/CPAF patients reported feeling more unhygienic, uncomfortable, and guilty about their condition toward family and friends than CD patients. They also found it more difficult to talk with family and close friends about their condition. PAF/CPAF patients avoided having sex, ended relationships, had arguments with partner, felt inadequate to partner, avoided dating and had their partner refuse having sex more often than CD patients. Furthermore, these patients were unable to play sports, carried a personal hygiene kit, were aware of access to clean toilets, and had changed profession/career due to their condition more often (Figure). Conclusion From the patients’ perspective, PAF/CPAF in CD severely impacts patients’ overall QoL, social and sexual relationships and work life. These results are important to consider when tailoring treatment strategy and patient services in a multidisciplinary way to address individual patient needs.


2020 ◽  
pp. 1-13
Author(s):  
Niels Teich ◽  
Michael Bläker ◽  
Frank Holtkamp-Endemann ◽  
Eric Jörgensen ◽  
Andreas Stallmach ◽  
...  

<b><i>Introduction:</i></b> Infliximab (IFX) therapy is efficacious for inducing and maintaining symptomatic remission in patients with Crohn’s disease (CD), but whether this benefit results in reduced hospitalization rates and therefore may improve patients’ quality of life in an economically sensible way is conflicting so far. <b><i>Methods:</i></b> We conducted a noninterventional, multicenter, open-label, prospective study to evaluate the effect of originator IFX treatment on patient-reported outcomes and disease-related hospitalizations in adult CD patients in Germany treated for the first time with IFX according to label. <b><i>Results:</i></b> Two hundred and ninety-four patients were included in the study. We observed a statistically significant reduction in the number of CD-related hospitalizations from the year before baseline (mean 1.00 per patient, SD ± 0.93) to the mean value of the 1st (0.62, SD ± 0.95) and 2nd year (0.32, SD ± 0.75) of the observation period (<i>p</i> &#x3c; 0.0001). After 3 months of IFX therapy, work productivity and activity increased by an average of 12.6 and 17.1%, respectively. Patient’s clinical outcome was markedly improved as the total CD activity index (CDAI) sum score continuously decreased from baseline to month 24 and the mean score of the total inflammatory bowel disease questionnaire (IBDQ) changed substantially from 141 at baseline to 172 after 24 months of IFX treatment. Additionally, the number of work incapacity days declined. Recently, no new safety issues of IFX have been identified. <b><i>Conclusion:</i></b> In this large, prospective, multicenter study on disease-related hospitalization rates, work productivity, capacity for daily activities, and HRQoL in patients with CD, IFX significantly reduces their hospitalization rates and improves work productivity, daily activity, and quality of life over 24 months.


2009 ◽  
Vol 136 (5) ◽  
pp. A-179 ◽  
Author(s):  
Edward V. Loftus ◽  
Jean-Frederic Colombel ◽  
Paul Rutgeerts ◽  
David T. Rubin ◽  
Naijun Chen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document